No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PPBT Purple Biotech
- 0.530
- -0.010-1.81%
Trading Jun 18 10:16 ET
13.85MMarket Cap-671P/E (TTM)
0.555High0.530Low33.51KVolume0.555Open0.540Pre Close18.16KTurnover0.14%Turnover RatioLossP/E (Static)26.11MShares1.80052wk High0.45P/B12.46MFloat Cap0.30252wk Low--Dividend TTM23.50MShs Float69.500Historical High--Div YieldTTM4.63%Amplitude0.302Historical Low0.541Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersViracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock in
Express News | Purple Biotech Ltd : Jonestrading Cuts Target Price to $3 From $8
Reported Saturday, Purple Biotech Revealed Results From A Phase 2 Study At ASCO 2024, Showing CM24 Improved Overall Survival And Other Efficacy Endpoints In Pancreatic Cancer
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(So
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) today announced positive interim data from its randomized, controlled, open label, multicenter Phase 2 study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma (PDAC) presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Express News | Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at Asco 2024 Demonstrating Cm24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer
12 Health Care Stocks Moving In Friday's Intraday Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) share
Comments
$Purple Biotech(PPBT.US$ Reported Saturday, Purple Biotech Revealed Results From A Phase 2 Study At ASCO 2024, Showing CM24 Improved Overall Survival And Other Efficacy Endpoints In Pancreatic Cancer
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim data
Prolongation of 2.1 months in median overall survival ...
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim data
Prolongation of 2.1 months in median overall survival ...
2
$Purple Biotech(PPBT.US$
I think this one will go to at least a dollar by the end of the month. good potential
I think this one will go to at least a dollar by the end of the month. good potential
2
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
11
2
$Purple Biotech(PPBT.US$ Between now and EOY there is going to be multiple data readouts/releases! And could be some good news come out of poster presentation on June 1st? Just thinking outloud! Hehehe![]()
3
6
$Purple Biotech(PPBT.US$
Purple Biotech Ltd., a biotech firm trading on NASDAQ/TASE as PPBT, has a strong financial standing with a cash balance of $15.3 million and is well-positioned for upcoming clinical trial readouts in 2024. The company focuses on developing innovative first-in-class drug candidates, including CM24 for pancreatic cancer, and boasts a pipeline of potential oncology therapies. With a cash runway into the first half of 2025, Purple Biotech is advancing its leading ...
Purple Biotech Ltd., a biotech firm trading on NASDAQ/TASE as PPBT, has a strong financial standing with a cash balance of $15.3 million and is well-positioned for upcoming clinical trial readouts in 2024. The company focuses on developing innovative first-in-class drug candidates, including CM24 for pancreatic cancer, and boasts a pipeline of potential oncology therapies. With a cash runway into the first half of 2025, Purple Biotech is advancing its leading ...
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg